4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 900.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,500.00
  • 52 Week Low: 875.00
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 2,829
  • Market Cap: £139.85m
  • Beta: 0.03

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth
87.49% above the market average87.49% above the market average87.49% above the market average87.49% above the market average87.49% above the market average
51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average51.72% above the sector average

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
93.70% above the market average93.70% above the market average93.70% above the market average93.70% above the market average93.70% above the market average
82.61% above the sector average82.61% above the sector average82.61% above the sector average82.61% above the sector average82.61% above the sector average
Price Book Ratio
81.31% below the market average81.31% below the market average81.31% below the market average81.31% below the market average81.31% below the market average
27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average27.78% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
70.69% below the market average70.69% below the market average70.69% below the market average70.69% below the market average70.69% below the market average
42.22% below the sector average42.22% below the sector average42.22% below the sector average42.22% below the sector average42.22% below the sector average
Price Chg 3m
77.59% below the market average77.59% below the market average77.59% below the market average77.59% below the market average77.59% below the market average
64.44% below the sector average64.44% below the sector average64.44% below the sector average64.44% below the sector average64.44% below the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI
46.3% below the market average46.3% below the market average46.3% below the market average46.3% below the market average46.3% below the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average
Momentum 20
93.49% below the market average93.49% below the market average93.49% below the market average93.49% below the market average93.49% below the market average
90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average90.48% below the sector average

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
94.37% below the market average94.37% below the market average94.37% below the market average94.37% below the market average94.37% below the market average
72.41% below the sector average72.41% below the sector average72.41% below the sector average72.41% below the sector average72.41% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
54.35% below the market average54.35% below the market average54.35% below the market average54.35% below the market average54.35% below the market average
16.28% below the sector average16.28% below the sector average16.28% below the sector average16.28% below the sector average16.28% below the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
81.96% below the market average81.96% below the market average81.96% below the market average81.96% below the market average81.96% below the market average
44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average44.83% below the sector average
Operating Profit Loss
85.22% below the market average85.22% below the market average85.22% below the market average85.22% below the market average85.22% below the market average
58.14% below the sector average58.14% below the sector average58.14% below the sector average58.14% below the sector average58.14% below the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
9.05% above the market average9.05% above the market average9.05% above the market average9.05% above the market average9.05% above the market average
40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average40.00% above the sector average
Cash
46.25% above the market average46.25% above the market average46.25% above the market average46.25% above the market average46.25% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y
18.80% above the market average18.80% above the market average18.80% above the market average18.80% above the market average18.80% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average
Buys 1y
70.57% above the market average70.57% above the market average70.57% above the market average70.57% above the market average70.57% above the market average
48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average48.39% above the sector average

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 900.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,500.00
52 Week Low 875.00
Volume 2,829
Shares Issued 15.54m
Market Cap £139.85m
Beta 0.03

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.1% below the market average65.1% below the market average65.1% below the market average65.1% below the market average65.1% below the market average
11.63% above the sector average11.63% above the sector average11.63% above the sector average11.63% above the sector average11.63% above the sector average
Price Trend
33.85% below the market average33.85% below the market average33.85% below the market average33.85% below the market average33.85% below the market average
11.11% above the sector average11.11% above the sector average11.11% above the sector average11.11% above the sector average11.11% above the sector average
Income Not Available
Growth
59.21% above the market average59.21% above the market average59.21% above the market average59.21% above the market average59.21% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average

4basebio Dividends

No dividends found

Trades for 14-Aug-2025

Time Volume / Share Price
08:07 1,304 @ 875.00p
08:07 1,064 @ 900.00p
09:00 221 @ 900.00p
08:06 240 @ 930.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page